MedElevator
Войти в исследования Gynecologic oncology reports · 2021
Percutaneous insertion of bilateral double J in pelvic cancer patients: Indications, complications, technique of antegrade ureteral stenting.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fabiano de Oliveira Leite Túlio, Vatanabe Pazinato Lucas, Mauricio da Motta Leal Filho Joaquim
Аннотация
BACKGROUND: Antegrade percutaneous insertion of a double J seems to be a good alternative when retrograde insertion fails. Malignant ureteral obstruction occurs due to occlusion of the ureter secondary to tumor invasion, extrinsic compression, which prevents intermittent urine flow, leading to acute renal failure, increased morbidity, mortality and interruption of cancer treatment.
CASE: A 26-year-old woman with endometrial carcinoma with internal invasion of pelvic structures due to urosepsis and acute renal failure. She underwent anterograde percutaneous double-J implantation by interventional radiology due to the failure of retrograde catheter implantation.
CONCLUSION: The antegrade double-J percutaneous implant technique is an alternative when the retrograde technique fails. This technique is feasible, with low morbidity and mortality and good quality of life for continuing cancer treatment.
CASE: A 26-year-old woman with endometrial carcinoma with internal invasion of pelvic structures due to urosepsis and acute renal failure. She underwent anterograde percutaneous double-J implantation by interventional radiology due to the failure of retrograde catheter implantation.
CONCLUSION: The antegrade double-J percutaneous implant technique is an alternative when the retrograde technique fails. This technique is feasible, with low morbidity and mortality and good quality of life for continuing cancer treatment.